394653-40-8

Basic information

• Product Name: (+/-)-3-oxetanylglycine methyl ester
• Synonyms: 3-Oxetaneacetic acid, a-aMino-, Methyl ester;Methyl-2-amino-1-(oxetan-3-yl)acetate
• CAS NO: 394653-40-8
• Molecular Formula: C₆H₁₁NO₃
• Molecular Weight: 145
• Mol File: 394653-40-8.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 201.4 °C at 760 mmHg
• Flash Point: 79.2 °C
• Appearance: /
• Density: 1.196 g/cm³
• Storage Temp.: Keep in dark place,Inert atmosphere,Store in freezer, under -20°C
• PKA: 6.88±0.50(Predicted)
• CAS DataBase Reference: (+/-)-3-oxetanylglycine methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: (+/-)-3-oxetanylglycine methyl ester(394653-40-8)
• EPA Substance Registry System: (+/-)-3-oxetanylglycine methyl ester(394653-40-8)

Safety Data

• Statements: 36
• Safety Statements: 26
• Hazardous Substances Data: 394653-40-8(Hazardous Substances Data)

Usage

General Description

(+/-)-3-oxetanylglycine methyl ester is a chemical compound that belongs to the family of oxetanes. It is a synthetic molecule that consists of a four-membered ring containing three carbon atoms and one oxygen atom. (+/-)-3-oxetanylglycine methyl ester is used in organic synthesis and medicinal chemistry as a building block for the creation of more complex molecules. It has potential applications in drug development, as it can be used as a precursor for the synthesis of pharmaceutical compounds. Additionally, the methyl ester functionality in this molecule allows for easy manipulation and modification of its chemical properties, making it a versatile tool in the field of organic chemistry.

Upstream product

• 394653-39-5 N-benzyloxycarbonyl-α,β-didehydro-(3-oxetanyl)glycine methyl ester 

Downstream Products

• 1408074-43-0 (R)-2-((tert-butoxycarbonyl)amino)-2-(oxetan-3-yl)acetic acid 
• 1255717-04-4 methyl 2-(benzyloxycarbonylamino)-2-(oxetan-3-yl)acetate 
• 1616889-73-6 C₁₃H₁₅NO₅ 
• 1213783-62-0 (S)-methyl 2-(benzyloxycarbonylamino)-2-(oxetan-3-yl)acetate 
• 1270019-87-8 2-amino-2-(oxetan-3-yl)acetic acid 

Relevant articles and documents

Improving the metabolic stability of antifungal compounds based on a scaffold hopping strategy: Design, synthesis, and structure-activity relationship studies of dihydrooxazole derivatives

L-amino alcohol derivatives exhibited high antifungal activity, but the metabolic stability of human liver microsomes in vitro was poor, and the half-life of optimal compound 5 was less than 5 min. To improve the metabolic properties of the compounds, the scaffold hopping strategy was adopted and a series of antifungal compounds with a dihydrooxazole scaffold was designed and synthesized. Compounds A33-A38 substituted with 4-phenyl group on dihydrooxazole ring exhibited excellent antifungal activities against C. albicans, C. tropicalis and C. krusei, with MIC values in the range of 0.03–0.25 μg/mL. In addition, the metabolic stability of compounds A33 and A34 in human liver microsomes in vitro was improved significantly, with the half-life greater than 145 min and the half-life of 59.1 min, respectively. Moreover, pharmacokinetic studies in SD rats showed that A33 exhibited favourable pharmacokinetic properties, with a bioavailability of 77.69%, and half-life (intravenous administration) of 9.35 h, indicating that A33 is worthy of further study.

CERAMIDE GALACTOSYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF DISEASE

Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with the enzyme ceramide galactosyltransferase (CGT), such as, for example, lysosomal storage diseases. Examples of lysosomal storage diseases include, for example, Krabbe disease and Metachromatic Leukodystrophy.

FUSED MORPHOLINOPYRIMIDINES AND METHODS OF USE THEREOF

The present disclosure relates to Fused Morpholinopyrimidines, pharmaceutical compositions comprising an effective amount of a Fused Morpholinopyrimidine and methods for using a Fused Morpholinopyrimidine in the treatment of a neurodegenerative disease, comprising administering to a subject in need thereof an effective amount of a Fused Morpholinopyrimidine.